Sydney, Australia – 5 August 2024 | LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that its innovative nasal spray treatment for Erectile Dysfunction (ED), named SPONTAN®, has been prescribed to the first patients under the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS). This milestone represents a significant step forward in addressing the unmet need for fast-acting, on-demand ED treatments.
Highlights:
-
First Prescription of SPONTAN®: SPONTAN® has been successfully prescribed to the first patients under the TGA’s Special Access Scheme, marking an important milestone for the Company.
-
Addressing Unmet Needs: SPONTAN® demonstrates the potential to fill a critical gap in the market for fast-acting ED treatments, offering a solution that works within 10 minutes or less; much faster than existing oral treatments.
-
Strategic Market Introduction: LTR Pharma’s KOL-led (Key Opinion Leader) strategy facilitates the strategic introduction of SPONTAN® to the market, enabling the collection of real-world data and increasing awareness within the medical community.
-
International KOL Engagement: The involvement of internationally recognised KOLs, such as Melissa Hadley Barrett, provides a platform for sharing experiences at international conferences and in scientific publications, further supporting the product’s market entry.
Lee Rodne, Chairman of LTR Pharma, stated: “The use of SPONTAN under the early access program marks a watershed moment for LTR Pharma. It demonstrates both the urgent need for fast-acting ED medication and SPONTAN’s potential to address a high unmet need for a fast and on-demand ED treatment and allows for hands-on, real-world experience with SPONTAN.”
Melissa Hadley Barrett, Founder of the Restorative Sexual Health Clinic, commented: “We see SPONTAN as a valuable addition to our therapeutic capability. SPONTAN complements our holistic approach, offering our patients an innovative option to help address their sexual health concerns and enhance overall well-being.”
About the Therapeutic Goods Administration’s Special Access Scheme:
The TGA’s Special Access Scheme enables health practitioners to access unapproved therapeutic goods for individual patients, assessed case-by-case. This milestone marks a pivotal advancement in the Company’s strategy to introduce SPONTAN to the market through a meticulously managed, KOL-driven approach. The SAS program facilitates off-market compassionate use of SPONTAN for patients with unmet medical needs, as determined by qualified healthcare professionals.
About us:
About LTR Pharma:
LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction (ED). ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma’s lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.
Contact details:
Jane Morgan
Jane Morgan Management
Investor & Media Relations
jm@janemorganmanagement.com.au